124 related articles for article (PubMed ID: 27327270)
21. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
22. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
Cencini E; Fabbri A; Bocchia M
Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
[No Abstract] [Full Text] [Related]
23. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
D'Arco AM; Califano C; Barone L; Belsito Petrizzi V; Iovino V; Langella M; Maglione V; Rivellini F; De Lorenzo S
Br J Haematol; 2015 Nov; 171(4):662-5. PubMed ID: 25873239
[No Abstract] [Full Text] [Related]
24. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
25. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
Sun HL; Atenafu EG; Tsang R; Kukreti V; Marras TK; Crump M; Kuruvilla J
Leuk Lymphoma; 2017 Nov; 58(11):2607-2614. PubMed ID: 28504035
[TBL] [Abstract][Full Text] [Related]
26. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.
Buchler T; Bomanji J; Lee SM
Haematologica; 2007 Nov; 92(11):e120-1. PubMed ID: 18024389
[TBL] [Abstract][Full Text] [Related]
27. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
Pinnix CC; Smith GL; Milgrom S; Osborne EM; Reddy JP; Akhtari M; Reed V; Arzu I; Allen PK; Wogan CF; Fanale MA; Oki Y; Turturro F; Romaguera J; Fayad L; Fowler N; Westin J; Nastoupil L; Hagemeister FB; Rodriguez MA; Ahmed S; Nieto Y; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):175-82. PubMed ID: 25863764
[TBL] [Abstract][Full Text] [Related]
28. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
29. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
[TBL] [Abstract][Full Text] [Related]
30. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
31. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
[TBL] [Abstract][Full Text] [Related]
33. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.
Avivi I; Hardak E; Shaham B; Igla M; Rowe JM; Dann EJ
Ann Hematol; 2012 Feb; 91(2):215-21. PubMed ID: 21603918
[TBL] [Abstract][Full Text] [Related]
34. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
35. Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease.
Villani F; Dell'Oca I; De Maria P; Viola G; Di Russo A; Viviani S; Bonfante V
Anticancer Res; 1999; 19(5C):4475-9. PubMed ID: 10650795
[TBL] [Abstract][Full Text] [Related]
36. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
[TBL] [Abstract][Full Text] [Related]
37. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
38. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
39. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
40. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
